Analysis of CD4+ T-cell responses to a novel α-fetoprotein-derived epitope in hepatocellular carcinoma patients

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6686-6694

  Alisa, Akeel ^a,b   Ives, Annette ^a   Pathan, Ansar A ^e   Navarrete, Cristina V ^c,d   Williams, Roger ^a,b   Bertoletti, Antonio ^a   Behboudi, Shahriar ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CROMWELL HOSPITAL   (United Kingdom)

^c North London Blood Centre   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CANCER VACCINE; CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN RECOGNITION; ARTICLE; BIOASSAY; BLOOD LEVEL; CELLULAR IMMUNITY; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINE PRODUCTION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; AMINO ACID SEQUENCE; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPITOPES; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 25144454922     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0382     Document Type: Article

References (23)

1. Beun GD, van de Velde CJ, Fleuren GJ. T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? Immunol Today 1994;15:11-5.
2. Grimm CF, Ortmann D, Mohr L, et al. Mouse α-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 2000;119:1104-12.
3. Kamata Y. The prevention of chemical hepatocarcinogenesis in rats by combining active and passive immunization with α-fetoprotein. Tumour Biol 1985;6:243-56.
4. Butterfield LH, Koh A, Meng W, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein. Cancer Res 1999;59:3134-42.
5. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-7.
6. Um SH, Mulhall C, Alisa A, et al. α-Fetoprotein impairs APC function and induces their apoptosis. J Immunol 2004;173:1772-8.
7. Peck AB, Murgita RA, Wigzell H. Cellular and genetic restrictions in the immunoregulatory activity of α-fetoprotein. II. α-Fetoprotein- induced suppression of cytotoxic T lymphocyte development. J Exp Med 1978;148:360-72.
8. Murgita RA, Tomasi TB Jr. Suppression of the immune response by α-fetoprotein on the primary and secondary antibody response. J Exp Med 1975;141:269-86.
9. Murgita RA, Goidl EA, Kontianen S, Wigzell H. α-Fetoprotein induces suppressor T cells in vitro. Nature 1977;267:257-9.
10. Bei R, Budillon A, Reale MG, et al. Cryptic epitopes on α-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res 1999;59:5471-4.
11. + hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma. Cell Immunol 1997;177:176-81.
12. Hanke P, Rabe C, Serwe M, et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human α-fetoprotein. Scand J Gastroenterol 2002;37:949-55.
13. Butterfield LH, Meng WS, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human a fetoprotein. J Immunol 2001;166:5300-8.
14. Vollmer CM Jr, Eilber FC, Butterfield LH, et al. α-Fetoprotein- specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999;59:3064-7.
15. Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Exp Opin Biol Ther 2002;2:123-33.
16. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
17. Hurley CK, Wade JA, Oudshoorn M, et al. A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hum Immunol 1999;60:347-60.
18. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995;46:355-67.
19. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Tissue Antigens 1997;49:297-321.
20. Malacarne F, Webster GJ, Reignat S, et al. Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment. J Infect Dis 2003;187:679-82.
21. Sato K, Tanaka M, Kusaba T, Fukuda H, Tanikawa K. Immunohistochemical demonstration of α-fetoprotein in small hepatocellular carcinoma. Oncol Rep 1998;5:355-8.
22. Ferber I, Schonrich G, Schenkel J, Mellor AL, Hammerling GJ, Arnold B. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994;263:674-6.
23. Ritter M, Ali MY, Grimm CF, et al. Immunoregulation of dendritic and T cells by α-fetoprotein in patients with hepatocellular carcinoma. J Hepatol 2004;41:999-1007.